202 related articles for article (PubMed ID: 18243516)
1. Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects.
Amend B; Hennenlotter J; Schäfer T; Horstmann M; Stenzl A; Sievert KD
Eur Urol; 2008 May; 53(5):1021-8. PubMed ID: 18243516
[TBL] [Abstract][Full Text] [Related]
2. Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage.
Horstmann M; Schaefer T; Aguilar Y; Stenzl A; Sievert KD
Neurourol Urodyn; 2006; 25(5):441-5. PubMed ID: 16847942
[TBL] [Abstract][Full Text] [Related]
3. Tolterodine for overactive bladder: time to onset of action, preferred dosage, and 9-month follow-up.
Atan A; Konety BR; Erickson JR; Yokoyama T; Kim DY; Chancellor MB
Tech Urol; 1999 Jun; 5(2):67-70. PubMed ID: 10458657
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of extended-release tolterodine for the treatment of neurogenic detrusor overactivity and/or low-compliance bladder.
Watanabe M; Yamanishi T; Honda M; Sakakibara R; Uchiyama T; Yoshida K
Int J Urol; 2010 Nov; 17(11):931-6. PubMed ID: 20969642
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters.
Humblet M; Verpoorten C; Christiaens MH; Hirche H; Jansen K; Buyse G; van Gool JD
Neurourol Urodyn; 2015 Apr; 34(4):336-42. PubMed ID: 24436114
[TBL] [Abstract][Full Text] [Related]
6. Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity?
Serati M; Salvatore S; Uccella S; Cardozo L; Bolis P
Eur Urol; 2009 Mar; 55(3):713-9. PubMed ID: 18584946
[TBL] [Abstract][Full Text] [Related]
7. Combined antimuscarinics for treatment of neurogenic overactive bladder.
Nardulli R; Losavio E; Ranieri M; Fiore P; Megna G; Bellomo RG; Cristella G; Megna M
Int J Immunopathol Pharmacol; 2012; 25(1 Suppl):35S-41S. PubMed ID: 22652160
[TBL] [Abstract][Full Text] [Related]
8. Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways.
Kim Y; Yoshimura N; Masuda H; de Miguel F; Chancellor MB
Urology; 2005 Feb; 65(2):238-42. PubMed ID: 15708029
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety of tolterodine in children with neurogenic detrusor overactivity.
Reddy PP; Borgstein NG; Nijman RJ; Ellsworth PI
J Pediatr Urol; 2008 Dec; 4(6):428-33. PubMed ID: 19013412
[TBL] [Abstract][Full Text] [Related]
10. Effects on bladder function of combining elocalcitol and tolterodine in rats with outflow obstruction.
Streng T; Andersson KE; Hedlund P; Gratzke C; Baroni E; D'Ambrosio D; Benigni F
BJU Int; 2012 Jul; 110(2 Pt 2):E125-31. PubMed ID: 22288904
[TBL] [Abstract][Full Text] [Related]
11. [High-dose trospium chloride in therapy of detrusor hyperreflexia].
Madersbacher H; Stöhrer M; Richter R; Giannetti BM; Mürtz G
Urologe A; 1991 Jul; 30(4):260-3. PubMed ID: 1926674
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
Kennelly MJ; Lemack GE; Foote JE; Trop CS
Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
[TBL] [Abstract][Full Text] [Related]
13. [Spasmex treatment of patients with hyperactive urinary bladder].
Pushkar' DIu; Shchaveleva OB
Urologiia; 2003; (4):46-9. PubMed ID: 12942728
[TBL] [Abstract][Full Text] [Related]
14. [Trospium chloride (spasmex) in the treatment of lower urinary tract symptoms in patients with neurogenic hyperactive urinary bladder caused by vertebrogenic lesions].
Mazo EB; Babanina GA
Urologiia; 2007; (3):15-9. PubMed ID: 17722614
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of overactive bladder in older women increased doses of antimuscarinic drugs safe and effective alternative to existing methods].
Kosilov KV; Loparev SA; Krasnykh MA; Kosilova LV
Adv Gerontol; 2014; 27(1):149-55. PubMed ID: 25051773
[TBL] [Abstract][Full Text] [Related]
16. [The use of intravesical oxybutynin hydrochloride in patients with neurogenic bladder managed by intermittent catheterization].
Yokoyama O; Ishiura Y; Nakamura Y; Ohkawa M
Hinyokika Kiyo; 1995 Jul; 41(7):521-4. PubMed ID: 7668182
[TBL] [Abstract][Full Text] [Related]
17. Combined low-dose antimuscarinics for refractory detrusor overactivity in children.
Fahmy A; Youssif M; Rhashad H; Mokhless I; Mahfouz W
J Pediatr Urol; 2016 Aug; 12(4):219.e1-5. PubMed ID: 27282551
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction.
Pannek J; Göcking K; Bersch U
BJU Int; 2009 Nov; 104(9):1246-50. PubMed ID: 19426192
[TBL] [Abstract][Full Text] [Related]
19. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity.
Reitz A; Stöhrer M; Kramer G; Del Popolo G; Chartier-Kastler E; Pannek J; Burgdörfer H; Göcking K; Madersbacher H; Schumacher S; Richter R; von Tobel J; Schurch B
Eur Urol; 2004 Apr; 45(4):510-5. PubMed ID: 15041117
[TBL] [Abstract][Full Text] [Related]
20. [Topical treatment with oxybutynin chloride in neurogenic incontinence].
López Pereira P; Martínez MJ; Muguerza R; Jaureguizar E
Cir Pediatr; 1993 Jan; 6(1):29-31. PubMed ID: 8499234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
